NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

So, I'll just address one of your points. Dr. Prins was discussing those subtypes that did not necessarily respond to DCVax-L when he discussed the striking results of combo treatment -- PD-1 inhibitors + DCVax-L. IMHO. Those subtypes that normally don't respond are typically cancers that are still aggressively advancing after SOC and just before DCVax-L treatment. Those subtypes were eliminated from the Phase III DCVax-L trial (although proneural potential 'non-responders' are in the trial to a certain extent) . However, "don't respond" is somewhat outdated when one considers the response in double rapid progressors found in the information arm study. The new dosing regimen may be partly responsible for that. That probably means those who respond within the main arm (expected n=348) and the arm of 32 pseudoprogressors are likely getting better results as well. Anyway, we will only find out when the results are released. Meanwhile it appears that big pharma is planning to conduct a combination trial with DCVax-L. I could really care less if shorts are quaking in their boots, but I'm elated cancer has something to fear this time.